Update your browser

Your browser (Internet Explorer) is out of date.

Update your browser for more security, comfort and the best experience on this site.

Exelixis, Inc.

Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer.

210 East Grand Avenue, San Francisco, CA 94080, United States

Profile Navigation
This is a community generated profile. If you would like to claim it, please contact us.

About

Our Company

Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounds, cabozantinib and cobimetinib, tells the story of our evolution as a company. Each of these compounds were discovered in our own laboratories and advanced by us into clinical development.

In addition, we have leveraged our earlier stage drug discovery and development capabilities to establish multiple partnerships and collaborations with leading pharmaceutical and biopharmaceutical partners. These alliances are designed to advance the development of multiple Exelixis-discovered therapies, and allow Exelixis to focus on maximizing the potential of cabozantinib, our internally-discovered inhibitor of multiple tyrosine kinases.

We believe that cabozantinib has the potential to treat a wide variety of cancers. The medicine received its first regulatory approval in 2012; since then, alongside our collaborators, we have advanced a broad, global clinical development program that is exploring cabozantinib’s potential in approximately 45 planned or ongoing clinical trials. Most recently, data from a phase 3 pivotal trial led to a second U.S. approval for cabozantinib as a treatment for patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. Cabozantinib is marketed as CABOMETYX™ in the United States for that purpose. Click here for important safety information about CABOMETYX. Ipsen has an exclusive license to commercialize cabozantinib outside of the United States, Canada and Japan, and is pursuing European Union approval for the same indication.

Markets

areas of proficiency

Company Type

Choose Company Type

Cancel

Company Size

11 - 30

Choose Company Size

Cancel

Contact Info

get in touch

  • Location:

    Other: 210 East Grand Avenue, San Francisco, CA 94080, United States